Strategies of hormonal prevention

Cancer Treatment and Research

Volumn 147, Issue , 2009, Pages 195-229

  Li, Yuxin ^b   Brown, Powel H ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EXEMESTANE; FENRETINIDE; GEFITINIB; LAPATINIB; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; DEEP VEIN THROMBOSIS; DIETARY INTAKE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIP FRACTURE; HORMONAL REGULATION; HOT FLUSH; HUMAN; INTERSTITIAL LUNG DISEASE; LIFESTYLE MODIFICATION; LUNG EMBOLISM; MASTECTOMY; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; OVARY CANCER; PATIENT SELECTION; PHYSICAL ACTIVITY; PREGNANCY; PRIORITY JOURNAL; RADIUS FRACTURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SPINE FRACTURE; UTERINE CERVIX DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 79953775995     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-09463-2_10     Document Type: Article

References (171)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1): 43-66.
2. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-4. (Pubitemid 46631679)
3. Beatson G. On the treatment ofinoperable cases of carcinoma of the mamma: suggestions for a newmethod oftreatment, with illustrative cases. Lancet 1896;148:101-7.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
5. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85(22):1819-27. (Pubitemid 23333614)
6. Lambe M, Hsieh CC, Chan HW, et al. Parity, age at first and last birth, and risk ofbreast cancer: apopulation-based studyinSweden. Breast Cancer Res Treat. 1996;38(3):305-11.
7. Medina D, Smith GH. Chemical carcinogen-induced tumorigenesis in parous, involuted mouse mammary glands. J Natl Cancer Inst. 1999;91(11):967-9. (Pubitemid 29272524)
8. Rajkumar L, Guzman RC, Yang J, et al. Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis. Proc Natl Acad Sci USA. 2001;98(20): 11755-9. (Pubitemid 32928801)
9. Russo IH, Koszalka M, Russo J. Comparative study of the influence ofpregnancy and hormonal treatment onmammary carcinogenesis. Br J Cancer. 1991;64(3):481-4.
10. Thordarson G, Jin E, Guzman RC, et al. Refractoriness to mammary tumorigenesis in parous rats: is it caused by persistent changes in the hormonal environment or permanent biochemical alterations in the mammary epithelia? Carcinogenesis. 1995; 16(11):2847-53.
11. Sinha DK, Pazik JE, Dao TL. Prevention of mammary carcinogenesis in rats by preg-nancy: effect offull-term and interrupted pregnancy. Br J Cancer. 1988;57(4):390-4.
12. Russo J, Moral R, Balogh GA, et al. The protective role ofpregnancy in breast cancer. Breast Cancer Res. 2005;7(3):131-42. (Pubitemid 40704134)
13. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. Breast Cancer Res. 2005;7(1):13-7. (Pubitemid 40214531)
14. Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology. 2007;18(1):137-57. (Pubitemid 46005918)
15. Lahmann PH, Friedenreich C, Schuit AJ, et al. Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007;16(1):36-42. (Pubitemid 46174261)
16. Irwin ML. Randomized controlled trials of physical activity and breast cancer preven-tion. Exerc Sport Sci Rev. 2006;34(4):182-93. (Pubitemid 44562943)
17. McTiernan A, Tworoger SS, Ulrich CM, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res. 2004;64(8):2923-8. (Pubitemid 38500634)
18. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 1975;15(4): 617-31.
19. Knight DC, Eden JA. A review of the clinical effects ofphytoestrogens. Obstet Gynecol. 1996;87(5 Pt 2):897-904.
20. Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evi-dence. J Clin Endocrinol Metab. 1998;83(7):2223-35. (Pubitemid 28503006)
21. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 2007;57(5):260-77. (Pubitemid 47620124)
22. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modifica-tion Trial. JAMA. 2006;295(6):629-42. (Pubitemid 43209065)
23. Prentice RL, Thomson CA, Caan B, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99(20):1534-43. (Pubitemid 351767234)
24. Michels KB, Mohllajee AP, Roset-Bahmanyar E, et al. Diet and breast cancer: a review of the prospective observational studies. Cancer. 2007;109(12 Suppl):2712-49. (Pubitemid 46906454)
25. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis ofcohort studies. JAMA. 1998;279(7):535-40. (Pubitemid 28113433)
26. van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis ofprospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152(6):514-27.
27. Lynch HT, Lynch J, Conway T, et al. Hereditary breast cancer and family cancer syndromes. World J Surg. 1994;18(1):21-31. (Pubitemid 24100689)
28. Lynch HT, Snyder CL, Lynch JF, et al. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol. 2003;21(4):740-53. (Pubitemid 46621912)
29. Wirk B. The role of ovarian ablation in the management of breast cancer. Breast J. 2005;11(6):416-24. (Pubitemid 41743416)
30. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-8. (Pubitemid 27208598)
31. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343(8899):692-5. (Pubitemid 24087847)
32. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-6. (Pubitemid 37310920)
33. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055-62. (Pubitemid 41095038)
34. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy ofbilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-7. (Pubitemid 33094870)
35. Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg. 1989;13(1):15-21. (Pubitemid 19096241)
36. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-64. (Pubitemid 32662123)
37. Brekelmans CT, Seynaeve C, Bartels CC, et al. Effectiveness ofbreast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19(4):924-30. (Pubitemid 32176266)
38. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateralprophylacticmastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77-84. (Pubitemid 29054841)
39. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst. 2002;94(19):1433-4. (Pubitemid 35243741)
40. Scottish Cancer Trials Breast Group and ICRF Breast Unit. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Guy's Hospital, London. Lancet. 1993; 341(8856):1293-8.
41. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002;20(10):2559-66. (Pubitemid 34525744)
42. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy ofPrimary Breast Cancer. J Clin Oncol. 2001;19(18):3817-27. (Pubitemid 32880060)
43. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-9. (Pubitemid 29424552)
44. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-22. (Pubitemid 34755669)
45. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-15. (Pubitemid 34755668)
46. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417-25. (Pubitemid 28309036)
47. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336(20):1465-71. (Pubitemid 27208615)
48. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976;35(6):1332-8.
49. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of devel-oping breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-86. (Pubitemid 20026073)
50. Bondy ML, Lustbader ED, Halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994;86(8):620-5. (Pubitemid 24143172)
51. Rockhill B, Spiegelman D, Byrne C, et al. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358-66. (Pubitemid 32229380)
52. Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-92. (Pubitemid 351767204)
53. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for riskprediction. Cancer. 1994;73(3):643-51. (Pubitemid 24046606)
54. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk ofbreast cancer. N Engl J Med. 1997;336(20):1409-15. (Pubitemid 27208599)
55. Frank TS, Deffenbaugh AM, Hulick M, et al. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2. Dis Markers. 1999;15 (1-3):89-92. (Pubitemid 29520747)
56. Berry DA, Iversen ES, Jr., Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701-12. (Pubitemid 34575644)
57. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111-30. (Pubitemid 38477070)
58. Santen RJ, Boyd NF, Chlebowski RT, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007;14(2):169-87. (Pubitemid 47242621)
59. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with prolif-erative breast disease and atypical hyperplasia. Cancer. 1993;71(4):1258-65. (Pubitemid 23054916)
60. Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates ofbreast fluid. J Natl Cancer Inst. 2001;93(23):1791-8. (Pubitemid 33150451)
61. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146-51. (Pubitemid 15192861)
62. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229-37. (Pubitemid 41058322)
63. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000;92(15):1217-27. (Pubitemid 30627730)
64. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-88. (Pubitemid 28439961)
65. Dooley WC, Ljung BM, Veronesi U, et al. Ductallavage fordetection of cellular atypiain women at high risk for breast cancer. J Natl Cancer Inst. 2001;93(21):1624-32. (Pubitemid 33094869)
66. Ozanne EM, Esserman LJ. Evaluation ofbreast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2043-52. (Pubitemid 40054296)
67. Lerner LJ, Holthaus FJ, Jr., Thompson CR. A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology. 1958;63(3):295-318.
68. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618-29. (Pubitemid 36210865)
69. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18(17):3172-86.
70. Honig SF. Tamoxifen for the reduction in the incidence ofbreast cancer in women at high risk for breast cancer. Ann N Y Acad Sci. 2001;949:345-8. (Pubitemid 34060000)
71. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamox-ifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479-84. (Pubitemid 19062522)
72. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2(8449):282 (Pubitemid 15047587)
73. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-67.
74. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-62. (Pubitemid 41672231)
75. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98-101. (Pubitemid 28321321)
76. Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99(4):283-90. (Pubitemid 47073491)
77. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352(9122):93-7. (Pubitemid 28321320)
78. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst. 2003;95(2):160-5. (Pubitemid 36193265)
79. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomisedwomen. Lancet. 2002;359(9312):1122-4.
80. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial amongwomen with hysterectomy. J Natl Cancer Inst. 2007;99(9):727-37. (Pubitemid 47073533)
81. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336): 817-24. (Pubitemid 35257944)
82. Cuzick J, Forbes JF, Sestak I, et al. Long-termresults oftamoxifenprophylaxisforbreast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272-82. (Pubitemid 47073490)
83. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300. (Pubitemid 36126189)
84. Decensi A, Gandini S, Serrano D, et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol. 2007;25(27):4201-9. (Pubitemid 47548559)
85. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA. 1997;94(25): 14105-10. (Pubitemid 28009717)
86. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337(23):1641-7. (Pubitemid 27510100)
87. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Inves-tigators. JAMA. 1999;282(7):637-45. (Pubitemid 29384151)
88. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189-97. (Pubitemid 29275701)
89. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes ofraloxifene evaluation. Breast Cancer Res Treat. 2001;65(2):125-34. (Pubitemid 32193616)
90. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751-61. (Pubitemid 39654569)
91. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk ofdeveloping invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41.
92. Sato M, Turner CH, Wang T, et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther. 1998;287(1):1-7. (Pubitemid 29140178)
93. Munster PN, Buzdar A, Dhingra K, et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol. 2001;19(7):2002-9. (Pubitemid 32705494)
94. Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003;21(6):1007-14. (Pubitemid 46594128)
95. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptormodulator. Clin Cancer Res. 2004;10(16):5403-17. (Pubitemid 39100477)
96. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-53. (Pubitemid 38529873)
97. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neopla-sia. Nat Rev Cancer. 2004;4(7):505-18.
98. Ke HZ, Foley GL, Simmons HA, et al. Long-term treatment oflasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004;145(4):1996-2005. (Pubitemid 38402409)
99. Labrie F, Champagne P, Labrie C, et al. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol. 2004;22(5):864-71. (Pubitemid 41103598)
100. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005;146(9):3999-4008. (Pubitemid 41175771)
101. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23(8):1636-43. (Pubitemid 46211418)
102. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431-42. (Pubitemid 36682823)
103. Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab. 1980;51(3):473-7. (Pubitemid 10022826)
104. Osborne CK, Fuqua SA. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994;32(1):49-55. (Pubitemid 24322247)
105. Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 1998;58(9):1872-5. (Pubitemid 28217461)
106. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131-9. (Pubitemid 34694019)
107. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combina-tion) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-10. (Pubitemid 37310221)
108. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2.
109. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile ofanastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7(8):633-43.
110. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71. (Pubitemid 41535367)
111. Goss PE, Ingle JN, Martino S, et al. A randomized trial ofletrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-802. (Pubitemid 37362955)
112. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92. (Pubitemid 38298988)
113. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety ofexemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559-70.
114. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamox-ifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res. 2003;163:96-103; discussion 264-6.
115. Vogel VG, Costantino JP, Wickerham DL, et al. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res. 2003;9(1 Pt 2):495S-501S. (Pubitemid 36105793)
116. Richardson H, Johnston D, Pater J, et al. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14(3):89-96.
117. Bevilacqua G, Silingardi V, Marchetti P. Exemestane for the prevention ofbreast cancer in postmenopausal unaffected carriers of BRCA1/2 mutations-Aromasin Prevention Study (Apres). In: 24th Annual San Antonio Breast Cancer Symposium; 2001; San Antonio: Breast Cancer Research and Treatment; 2001. p. S226.
118. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev. 2001;81(3):1269-304. (Pubitemid 32606670)
119. Veronesi U, De Palo G, Marubini E, et al. Randomized trial offenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91(21):1847-56.
120. Decensi A, Serrano D, Bonanni B, et al. Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia. 2003;8(1):19-30. (Pubitemid 38129948)
121. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17(7): 1065-71. (Pubitemid 43985241)
122. Wu K, Kim HT, Rodriquez JL, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomar-kers Prev. 2002;11(5):467-74. (Pubitemid 34517942)
123. Wu K, Kim HT, Rodriquez JL, et al. 9-cis-Retinoic acid suppresses mammary tumor-igenesis in C3 (1)-simian virus 40 T antigen-transgenicmice. Clin Cancer Res. 2000;6(9): 3696-704.
124. Anzano MA, Byers SW, Smith JM, et al. Preventionofbreastcancerintheratwith9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994;54(17):4614-7. (Pubitemid 24276483)
125. Wu K, Zhang Y, Xu XC, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002;62(22):6376-80. (Pubitemid 35364089)
126. Li Y, Zhang Y, Hill J, et al. The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor Negative Tumors in MMTV-erbB2 Mice. Clin Cancer Res. 2007;13(20):6224-31. (Pubitemid 350075084)
127. Lu C, Speers C, Zhang Y, et al. Effect ofepidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003;95(24):1825-33. (Pubitemid 38054683)
128. Nagaria NC, Cogswell J, Choe JK, et al. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol. 2005;23(10):2423-4. (Pubitemid 46218736)
129. Strecker TE, Brown PH. Lapatinib, in preparation.
130. McNeil C Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst. 2006;98(16):1102-3.
131. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001;84(9):1188-92. (Pubitemid 32511336)
132. Johnson TW, Anderson KE, Lazovich D, et al. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1586-91. (Pubitemid 36020011)
133. Zerkowski MP, Camp RL, Burtness BA, et al. Quantitative analysis ofbreast cancer tissue microarrays shows high cox-2 expression is associated withpoor outcome. Cancer Invest. 2007;25(1):19-26. (Pubitemid 46423585)
134. Liu CH, Chang SH, Narko K, et al. Overexpression ofcyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276(21):18563-9.
135. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance ofelevated cyclooxygen-ase-2 expression in breast cancer. Cancer Res. 2002;62(3):632-5. (Pubitemid 34126931)
136. Harris RE, Alshafie GA, Abou-Issa H, et al. Chemoprevention ofbreast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000;60(8):2101-3. (Pubitemid 30225166)
137. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002;62(19):5405-7.
138. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk ofheart attack and stroke. BMJ. 2005; 330(7489):440.
139. Thorat MA, Morimiya A, Mehrotra S, et al. Prostanoid receptor EP1 expression in breast cancer. Mod Pathol. 2008;21(1):15-21.
140. Ma X, Kundu N, Rifat S, et al. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res. 2006;66(6):2923-7.
141. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth
142. Clay CE, Namen AM, Atsumi G, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20(10):1905-11. (Pubitemid 29476115)
143. Suh N, Wang Y, Williams CR, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcino-genesis. Cancer Res. 1999;59(22):5671-3.
144. Yin F, Bruemmer D, Blaschke F, et al. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene. 2004;23(26):4614-23. (Pubitemid 38850409)
145. Mehta RG, Williamson E, Patel MK, et al. A ligand of peroxisome proliferator-acti-vated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst. 2000;92(5):418-23. (Pubitemid 30154824)
146. Larsson SC, Kumlin M, Ingelman-Sundberg M, et al. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr. 2004;79(6):935-45. (Pubitemid 41095944)
147. Mehta RG, Hussain EA, Mehta RR, et al. Chemoprevention ofmammary carcinogen-esis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat Res. 2003; 523-524:253-64. (Pubitemid 36293252)
148. Matsumoto H, Iino Y, Koibuchi Y, et al. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep. 1999;6(2):349-52.
149. Hussain EA, Mehta RR, Ray R, et al. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and ther-apy. Recent Results Cancer Res. 2003;164:393-411.
150. Abe J, Nakano T, Nishii Y, et al. A novel vitamin D3 analog, 22-oxa-1,25-dihydrox-yvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology. 1991;129(2):832-7.
151. Lev DC, Kim SJ, Onn A, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res. 2005;11(1):306-14. (Pubitemid 40075809)
152. Davis T, Kennedy C, Chiew YE, et al. Histone deacetylase inhibitors decrease prolifera-tion and modulate cell cycle gene expression in normal mammary epithelial cells. Clin Cancer Res. 2000;6(11):4334-42.
153. Margueron R, Duong V, Castet A, et al. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol. 2004;68(6):1239-46. (Pubitemid 39094290)
154. Davidson NE, Hahm HA, McCloskey DE, et al. Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer. 1999;6(1):69-73. (Pubitemid 29197231)
155. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002;8(10):3105-17. (Pubitemid 35155020)
156. Winding B, NicAmhlaoibh R, Misander H, et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res. 2002;8(6):1932-9. (Pubitemid 34633756)
157. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol. 2005;23(8):1782-90. (Pubitemid 46211430)
158. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007;7(5):357-69. (Pubitemid 46652485)
159. Wang Y, He QY, Chen H, et al. Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res. 2007;313(2): 357-68. (Pubitemid 46048821)
160. Aoyama Y. Experimental studies on the effects of the combined use ofiV-(4-hydroxy-phenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer. Kurume Med J. 2002;49(1-2):27-33. (Pubitemid 34987700)
161. Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of MNU-induced mam-mary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 1992;12(4): 1147-53.
162. Suh N, Lamph WW, Glasebrook AL, et al. Prevention and treatment ofexperimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res. 2002;8(10):3270-5. (Pubitemid 35155040)
163. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res. 2004;64(10): 3566-71. (Pubitemid 38657933)
164. Liby K, Rendi M, Suh N, et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model ofbreast cancer. Clin Cancer Res. 2006;12(19):5902-9. (Pubitemid 44629624)
165. Elstner E, Williamson EA, Zang C, et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 2002;74(2):155-65. (Pubitemid 34816221)
166. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005;23(2):254-66. (Pubitemid 46206877)
167. Buchanan FG, Wang D, Bargiacchi F, et al. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278(37):35451-7. (Pubitemid 37102315)
168. Tortora G, Caputo R, Damiano V, et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003;9(4):1566-72. (Pubitemid 36418415)
169. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002;20(15):3328-43. (Pubitemid 34831530)
170. Chemoprevention ofbreast cancer: recommendations and rationale. Ann Intern Med. 2002;137(1):56-8.
171. Hollingsworth AB, Singletary SE, Morrow M, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg. 2004;187(3):349-62. (Pubitemid 38299500)